A single course of adjuvant bleomycin, etoposide and cisplatin chemotherapy appeared safe and effective among a cohort of men with high-risk primary testicular cancer, according to results of the phase 3, single-arm, prospective 111 study published in European Urology.

“Men with stage I nonseminoma germ cell tumors of the testis have an excellent prognosis, but a subgroup with lymphovascular invasion in the primary site have a high risk for recurrence that requires intensive chemotherapy as salvage therapy, and about one-third have subsequent major surgery,” Robert Huddart, MBBS, MRCP, FRCR, PhD, professor in the department of urological cancer at The Institute of Cancer Research in the U.K., told Healio.